Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Pfizer Rare Disease Plans Back On Track With Resubmission of Tafamidis

Feb 15 2012

• By Shirley Haley

Related Content

Auxilium's Xiaflex Clears FDA With REMS To Educate Doctors On Safe Injection Techniques

Feb 03 2010

Pfizer Adds To Specialty Care Division With Purchase Of FoldRx

Sep 01 2010

FDA Sends Back Filing For Pfizer's Tafamidis, Acquired in FoldRx Deal

Apr 04 2011

Deals Of The Week: Pfizer/Humana, Teva/Par, Bayer/Yunona

Oct 17 2011

FDA Delays Approval Of Protalix/Pfizer Gaucher Drug; Seeks More Data From Late-Stage Trials

Feb 25 2011

Sutent Cleared For Pancreatic Tumors, But With Caveat On Efficacy

May 23 2011

Pfizer’s Crizotinib Eases Past FDA With Targeted Population

Aug 29 2011

Tofacitinib Data Is In: As Effective As Humira, But Safety Remains A Question

Sep 12 2011

Related Companies

Pfizer Inc.

Protalix BioTherapeutics, Inc.

Sanofi

Sanofi Genzyme

Takeda Pharmaceutical Co. Ltd.

BioMarin Pharmaceutical Inc.

Auxilium Pharmaceuticals, Inc.

GlycoMimetics, Inc.

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window